CoChat

Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss

Badurdeen, Dilhana, Hoff, Anna Carolina, Hedjoudje, Abdellah, Adam, Atif, Itani, Mohamad I., Farha, Jad, Abbarh, Shahem, Kalloo, Anthony N., Khashab, Mouen A., Singh, Vikesh K., Oberbach, Andrea, Neto, Manoel Galvao, Barrichello, Sergio, Kumbhari, Vivek · 2021 · Gastrointestinal Endoscopy
Cited by 72

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND AIMS The endoscopic sleeve gastroplasty (ESG) has been shown to be effective for inducing weight loss. The efficacy of liraglutide, a glucagon-like peptide-1 agonist, to augment weight loss after ESG is unknown. This study aims to evaluate the efficacy of ESG and liraglutide (ESG-L) compared with ESG alone. METHODS This was a retrospective study of prospectively collected data from patients undergoing ESG at 3 outpatient clinics in Brazil, between November 2017 and July 2018. Liraglutide was offered to all patients 5 months after ESG. Patients that opted to take liraglutide (ESG-L) were matched 1:1 to patients that declined it (ESG). Primary outcome was percent total body weight loss (%TBWL), and percent excess weight loss (%EWL) 7 months after initiation of liraglutide (12 months after ESG). Secondary outcome was change in percent body fat 12 months after ESG. ESG technique and postprocedure follow-up was identical at all 3 sites. RESULTS Propensity score matching yielded 26 matched pairs. Adjusted comparisons between the 2 groups showed that patients who opted to take liraglutide had a superior mean %TBWL 7 months after initiation of liraglutide (ESG-L) compared with those that declined it (ESG), 24.72 ± 2.12% versus 20.51 ± 1.68% (p <0.001). ESG-L had a statistically greater reduction in percent body fat compared with ESG, 7.85 ± 1.26 versus 10.54 ± 1.88 (p <0.001) at 12 months. CONCLUSION Addition of liraglutide at 5 months results in superior weight loss and improved efficacy as demonstrated by decreased body fat 12 months after the ESG. Further studies are imperative to determine optimal dose, timing, and duration of liraglutide.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.gie.2020.10.016

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 72

Metadata

Authors
Badurdeen, D., Hoff, A. C., Hedjoudje, A., Adam, A., Itani, M. I., Farha, J., Abbarh, S., Kalloo, A. N., Khashab, M. A., Singh, V. K., Oberbach, A., Neto, M. G., Barrichello, S., & Kumbhari, V.
Venue
Gastrointestinal Endoscopy
Publisher
Elsevier BV
Published
2021-06
Volume
93
Issue
6
Pages
1316-1324.e1
ISSN
0016-5107 (ISSN-L)
OpenAlex
W3092665842
Cited by
72
References
18
FWCI
4.93
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss. https://app.cochat.ai/papers/10.1016/j.gie.2020.10.016
The paper
Badurdeen, D., Hoff, A. C., Hedjoudje, A., Adam, A., Itani, M. I., Farha, J., Abbarh, S., Kalloo, A. N., Khashab, M. A., Singh, V. K., Oberbach, A., Neto, M. G., Barrichello, S., & Kumbhari, V. (2021). Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss. Gastrointestinal Endoscopy. https://doi.org/10.1016/j.gie.2020.10.016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.